Business Context and Reporting Period
This Form 8-K is a current report filed by Catalyst Biosciences, Inc. (trading symbol: CBIO) on August 27, 2019. The filing reports a corporate governance event regarding the departure of a senior executive. Note: The request metadata references "Gyre Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Catalyst Biosciences, Inc.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is limited to reporting a personnel change.
Material Changes
- Executive Departure: Fletcher Payne voluntarily resigned as Chief Financial Officer (CFO), effective August 30, 2019.
- Reason: Mr. Payne is pursuing another opportunity.
- Transition Plan: The Company is initiating a search for a replacement CFO. Mr. Payne has agreed to provide consulting services post-resignation to assist with the transition of responsibilities.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary on business performance. The primary risk disclosed is the operational impact of the CFO vacancy, which the company is addressing through a replacement search and interim consulting support.
Investor Verification Checklist
- Verify the timeline for the appointment of a new Chief Financial Officer.
- Review the attached press release (Exhibit 99.1) for additional details on the transition.
- Confirm the current status of the company's financial reporting team during the interim period.